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Interleukin-1 induces natriuresis in conscious rats: Role of renal prosta-
glandins. The onset of infection is associated with increases in renal
blood flow and sodium excretion. Our studies provide evidence that the
natriuresis is mediated by stimulation of renal prostaglandin production
by the cytokine, interleukin-l. A dose-dependent natriuresis and diure-
sis was elicited in conscious rats with bolus intravenous injections of
human recombinant interleukin-1-/3 (hrlL-l). Injection of 1.5, 3 and 24
g hrIL-1 increased sodium excretion by 2.4 0.9 pEq/min, 4.0 0.8
Eq/min and 5.4 0.3 zEq/min, respectively. The natriuresis was
preceded by a corresponding increase in urinary PGE excretion (80%,
110% and 296%, respectively). The natriuresis elicited by 3 g hrIL-l
was independent of changes in glomerular filtration rate or effective
renal plasma flow. IL-I induced an increase in rectal temperature, (0.6
0.2°C) and a modest increase in mean arterial pressure (12 3 mm
Hg) within 10 minutes of injection. However, during the period of
maximal natriuresis (40 to 100 mm), blood pressure and rectal temper-
ature were not significantly different from control. Pretreatment with
the cyclooxygenase inhibitor, ibuprofen, significantly attenuated the
natriuretic response and indomethacin completely abolished the natri-
uresis. These results identify IL-I as a factor which stimulates renal
PGE synthesis, and increases sodium excretion, independent of changes in
glomerular filtration rate. We propose that IL-i-induced natriuresis may
be a component of the overall acute phase response which is actively
mounted by the host during infection.
At the onset of infection, many other rapid alterations of
central nervous, endocrine and hepatic function occur, fever
being perhaps the most apparent. Many of these changes are
not caused directly by exogenous pathogens, but instead com-
prise an active response of the host [9, 10]. Collectively these
changes are known as the acute phase response and are
mediated by a host-derived protein hormone, interleukin-1
(IL-i), which is secreted by monocytes and macrophages [111.
We recently reported that natriuresis could be induced in rats
by intravenous injection of human recombinant IL-i [12]. These
studies, now reported in detail, identify IL-i as the mediator of
natriuresis associated with infection, and suggest that natriure-
sis might best be considered part of the acute phase response.
Some of the effects of interleukin- I, such as fever and muscle
proteolysis, are mediated by stimulation of prostaglandins
whereas others are independent of prostaglandins [11]. A natri-
uretic role of renal prostaglandins has been suggested previ-
ously [13]. Therefore, we hypothesized that renal prostaglan-
dins may mediate IL-I-induced natriuresis. Accordingly, the
present studies investigated the effect of IL-i on urinary PGE
excretion, and the effect of cyclooxygenase inhibition on the
natriuretic response.
Infection is often associated with increases in renal blood
flow, sodium excretion, and urine flow. These responses occur
early, often observed in advance of other symptoms in humans
[11 and evident in experimental animals within 90 minutes of
infection [2, 3]. Both natriuresis and hyperemia can be induced
by bacterial and viral pathogens [1, 4, 5], endotoxin [2, 6, 7] and
pyrogenic inulin [8].
The specific mechanisms which cause increased sodium
excretion during infection are unknown. It has been thought
that the natriuresis of infection may be secondary to renal
vasodilation, since hyperemia and natriuresis occur simulta-
neously [3, 7]. Gagnon, Ramwell and Flamenbaum [51 reported
that the increase in renal blood flow is prostaglandin dependent,
whereas the role of prostaglandins in the natriuresis has not
been studied.
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Methods
Interleukin-1 preparations
The eDNA for human IL-I-p [141 was expressed in E. co/i
which yielded a 24 kD precursor molecule (amino acids 7 1-269).
The precursor was cleaved by protease treatment to its mature
form (17.3 kD) and then purified by HPLC as described
previously [151. The hrIL-1-/3 used in these experiments con-
sisted of amino acids 112-269 of the IL- l-/3 precursor. IL-I was
also purified from the supernatants of adherent human blood
monocytes in minimal essential medium which had been stim-
ulated with heat killed Staphylococcus a/bus, then incubated
for 24 hours at 37°C. The supernatants were purified by im-
munoaffinity chromatography followed by gel filtration, as
reported previously [16, 17].
Animals
Male Sprague-Dawley rats (250 to 350 g) were implanted with
chronic catheters in the bladder, carotid artery and jugular vein,
then studied at least two days following recovery from surgery
while conscious and restrained, Rats were conditioned to the
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restraint procedure three to five times prior to the experiment.
Details of the conscious rat preparation have been described
previously [18].
Clearance experiments
Urinary Na excretion, K excretion, urine flow rate, rectal
temperature and renal and systemic hemodynamics were mea-
sured in six rats injected with 3 g hrIL-l. The rats were placed
in a plastic restraint cage, where they remained for a 60 minute
adjustment period. The protocol consisted of four 20 minute
control periods after which the rats were injected with 3 j,g
human recombinant IL-i-/3 (hrIL-l). Six experimental periods
followed.
Effective renal plasma flow and glomerular filtration rate
were determined by the clearance of [3H1-PAH and l'4C1-inulin,
respectively. A priming dose of PAH and inulin dissolved in
0.9% NaCl was injected and followed by a maintenance infusion
at a rate of 13 p1/mm. Clearance periods were begun after 20
minutes of inulin infusion. Urine collections were obtained by
flushing the bladder with 2 ml of distilled water followed by 3 ml
of air, in order to minimize urinary dead space. Arterial blood
samples (75 p1) were collected one minute before the midpoint
of the clearance period, and hematocrit determined. Arterial
pressure was monitored throughout the experiment by connect-
ing the carotid arterial catheter to a Hewlett Packard pressure
transducer. Heart rate was determined at 20 minute intervals.
Rectal temperatures were measured with a Yellow Springs
Instruments telethermometer.
Dose-response experiments
Na and K excretion, urine flow and rectal temperature were
measured in five additional groups of rats. Rats in these groups
received: 1.5 .tg hrIL-l, (N 4); 3 ig hrIL-l (N =6); 24 g hr
IL-i, (N 5), human monocyte-derived IL-i (0.3 rabbit pyro-
gen dose, N 4), or saline (0.25 ml, N = 6). Experimental
protocols were as described above, except inulin clearance,
PAH clearance and blood pressure were not measured.
Urinary PGE excretion was also measured in the three
groups of rats injected with hrIL-l. Urine samples for PGE
analysis were placed on ice immediately after collection, and
stored at —70°C.
Cyclooxygenase inhibition
Sodium excretion, K excretion, urine flow and urinary POE
excretion were measured in two groups of rats receiving 3 g
hrIL-1 following inhibition of prostaglandin synthesis. The
cyclooxygenase inhibitors ibuprofen and indomethacin were
used to inhibit prostagiandin synthesis. Rats in one group (N
7) were injected with 10 mg/kg ibuprofen (Upjohn, formulated
for parenteral use) 40 minutes prior to the start of the experi-
ment, followed by a constant infusion (6.5 mg/kg/hr). Another
group of rats (N = 5) received indomethacin (4 mg/kg, i.p.)
three hours prior to the experiment, 1 mg/kg i.v. one hour prior
to the experiment, and a constant infusion of 5 mg/kg/hr
throughout the experiment. The indomethacin solution was
prepared by dissolving 25 mg indomethacin in 0.25 ml 0.5 M
sodium carbonate, then adding 1 ml distilled water, 1 ml 0.05 M
HC1 and 7 ml Krebs-Henseleit bicarbonate buffer.
PGE radioimmunoassay
Prior to extraction, the samples were acidified to pH 3.0 with
sodium citrate buffer and 3H-PGE2 added to assess recovery.
The samples were then extracted by passing through octadecyl-
silica (Sep-Pak C,8, Waters Associates) cartridges [191. Recov-
ery of 3H-PGE2 varied between 80% and 95%. PGE was
determined by radioimmunoassay with the use of a commercial
kit (Seragen, Cambridge, Massachusetts, USA) which employs
PGE2 as standard, and an antibody that displays 100% cross-
reactivity with POE,. Thus values are reported as POE, but
probably represent PGE2 since PGE1 is not present in urine in
significant quantities [20].
Analytical methods
Urinary Na and K concentrations were determined by flame
photometry. [3H]-PAH and ['4C1-inulin concentrations were
determined by liquid scintillation counting. Statistical signifi-
cance was determined by analysis of variance for repeated
measures [211, followed by Dunnet's test [221.
Results
Clearance experiments
Sodium excretion began to increase within 20 minutes of
injection of 3 g hrIL-l (Fig. 1), and was maximal at 40 to 80
minutes. At the peak of the natriuresis, sodium excretion had
increased fourfold over control values. The natriuresis was
associated with a parallel diuresis and unchanged potassium
excretion. Sodium excretion was unchanged in rats which were
injected with the hrIL-l vehicle (0.25 ml saline).
The effect of 3 g hrIL-l on renal clearance and blood
pressure measurements is shown in Figure 2. Effective renal
plasma flow was not significantly changed following injection of
hrIL-1 (P 0.17). Similarly, hrIL-l had no effect on glomerular
filtration rate (P = 0.49). Mean arterial pressure was signifi-
cantly increased 12 3 mm Hg (from 112 2 mm Hg to 124
4 mm Hg, P < 0.05), 10 minutes following the hrIL-1 injection,
Heart rate increased in parallel, from 406 18 bpm to 481 24
bpm (P < 0.05). However, heart rate and blood pressure were
not significantly different from control by 30 minutes, when
sodium excretion was increasing. The febrile response also
preceeded the natriuretic response. Rectal temperature was
significantly increased 15 to 20 minutes following the injection,
but had decreased to near baseline values by 40 minutes, when
natriuresis was maximal. Arterial hematocrit was unchanged
following administration of hrIL-l.
Dose-response effect of IL-I on sodium excretion and fever
Injection of hrIL-l caused a dose-related increase in sodium
excretion. The maximal increments in sodium excretion which
occurred following injection of three different doses of hrlL-1
are shown in Figure 3. Following injection of 1.5 and 3 g
hrIL-l, the maximal increments in sodium excretion were 2.4
0.9 pEq/min, 4.0 0.8 Eq/min and 5.4 0.3 pEq/min,
respectively. The natriuresis produced by all three doses of
hrIL-1 was associated with increased urine flow, while potas-
sium excretion was unchanged.
A similar natriuretic response occurred following injection of
highly purified IL-i obtained from human monocytes. Injection
of monocyte derived IL-i (0.3 rabbit pyrogen dose) increased
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Fig. 1. Effect of 3 ,isg hrIL-1-[3 on sodium excretion, potassium excre-
tion and urine flow. Bolus injection of hrIL-l (N 6) or vehicle (0.25 ml
saline, N = 6) were given at time = 0. Values shown are mean SE.
<0.05, < 0.01, different from pre-injection values.
sodium excretion from 0.6 0.2 Eq/min to a maximal rate of
2.2 0.6 tEq/min at 40 to 60 minutes (N 4, data not shown).
Urine flow increased in parallel, and potassium excretion was
unchanged.
Injection of either 1,5 or 3 rg of hrIL-l produced an increase
in rectal temperature. The maximal increments were 0.55
0.13°C and 0.69 0.16°C, respectively (Fig. 3). Injection of 24
rg hrIL-1 did not result in a significant febrile response; the
increment in rectal temperature was not significantly different
from the temperature change in rats injected with saline. This is
consistent with previous studies in rodents [231, in which the
febrile responses elicited by increasingly larger doses of IL-i
were smaller than those induced by the maximally effective
dose.
Dose-response effect of IL-i on urinary PGE excretion
Intravenous injection of hrIL-l resulted in a rapid increase in
urinary PGE excretion. Figure 4 displays the maximal 20-
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Fig. 2. Rectal temperature, renal and systemic hemodynamics associ-
ated with the natriuretic response to 3 p.g hrIL-I (Fig. 1). Rectal
temperature was calculated as the difference between the experimental
value and average pre-injection value which was 37.6 0.2°C. p <
0.05, signifIcantly different from pre-injection values.
minute PGE excretion rates occurring during the first 40 min-
utes following the hrIL-l injection. For most of the rats (11 of
14) the maximal increase in PGE excretion occurred 20 to 40
minutes following the injection. The increase was transient;
PGE excretion was not significantly different from control by 60
to 80 minutes following the hrIL-l injection. The complete
temporal relationship between PG stimulation and natriuresis
produced by the largest dose of hrIL-1 is shown in Figure 5.
Increased PGE excretion preceeded the natriuresis.
The stimulatory effect of hrIL-1 on urinary PGE was dose
related. Following injection of 1.5 ig hrIL-1, PGE excretion
increased from 358 70 pg/mm to 582 16 pg/mm, or by 81%
33% (N = 4). Rats injected with 3 sg had a lower initial PGE
excretion rate (227 51 pg/mm) which increased by 110%
1.4.
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Fig. 3. Comparison between natriuretic and pyrogenic effects of three
doses of hrIL-1: saline (N 6), 1.5 jig (N =4), 3 jig (N 7), 24 jig (N
= 5). The peak response was calculated as the maximal change of each
rat over pre-injection values. Average values of control sodium excre-
tion for each group were: 1.4 0.2 jiEq/min (saline), 1.5 0.4 jtEq/min
(1.5 jig), 0.8 0.2 jiEq/min (3 jig), and 2.2 0.5 jiEq/min (24 jig).
Average rectal temperatures preceeding the injection were 37.7
0.2°C, 37.7 0.2°C, 37.6 0.2°C, and 37.8 0.3°C, respectively. The
peak natriuretic response occurred 40 to 80 mm following IL-i injec-
tion, whereas the peak febrile response occurred at 10 to 30 mm.
0.05, < 0.01, significantly different from response of rats receiving
saline.
36% (N = 6) to 421 76 pg/mm. Following injection of the
largest dose, 24 rg, PGE excretion was increased by 296%
29% (N = 4). Thus, the magnitude of increased urinary PGE
was related to the dose as was the magnitude of the natriuretic
response.
Cyclooxygenase inhibition
The effect of hrIL-1 on sodium excretion was diminished in
rats pretreated with either of the cyclooxygenase inhibitors,
indomethacin or ibuprofen. Figure 6 demonstrates the effect of
indomethacin and ibuprofen on the natriuretic response to 3 j.g
hrIL-1. Pretreatment with ibuprofen significantly attenuated the
natriuretic response (P = 0.025). Sodium excretion was un-
changed by IL-I in four of eight rats pretreated with ibuprofen,
5 7
1.5p.g 3jig 24 jig 3jig 3p.g
+ INDO + IBU
Dose IL-i
Fig. 4. Dose-related stimulation of urinaly PGE by fir!!,-! Symbols
are: Open bars, average 0 to 80 mm prior to hrlL-l: solid bars, maximal
20 mm PGE excretion rate 0 to 40 mm following hrIL-1; shaded bars, 60
to 80 mm following injection, which also corresponded to the time of
maximal natriuresis. Urinary PGE was not increased by 3 jig hrlL-l in
rats pretreated with a cyclooxygenase inhibitor. < 0.05, <
0.025, signilicantly different from control PGE excretion.
Discussion
These studies provide evidence that IL-I is natriuretic in
vivo, and support the hypothesis that IL-l mediates the natri-
uresis which is associated with infection [I, 2, 3, 71. The two
lowest doses of IL-I which induced natriuresis in these studies
(1.5 and 3 p.g, or 5 to 10 tg/kg) are similar to the threshold doses
necessary to cause fever and other systemic acute phase
responses in rabbits, mice Fl5} and rats [241. Furthermore, in
renal infection tissue concentrations of IL-I could become
elevated with no change in systemic concentrations due to local
production by mesangial cells [25] or macrophages. 'rhus, a role
of endogenous IL-I in natriuresis is suggested. In contrast, our
result did not provide evidence of a role of IL-I in renal
hyperemia, another predominant renal change associated with
infection [3—81. A dose of IL-I which elicited a marked natri-
uresis did not increase renal blood flow.
IL-l-induced natriuresis could not be attributed to any hemo-
dynamic changes associated with hrlL-l injection. First, the
natriuresis does not appear to be related to the slight increase in
blood pressure. Although blood pressure was significantly
increased by 12 mm Hg during the first 20 minutes following
injection of IL-I, blood pressure returned toward control values
and was not significantly increased at the time of maximal
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increased slightly in two rats, while two rats demonstrated a
substantial natriuretic response. Pretreatment with indometh-
acm completely blocked the natriuresis in all rats. Both inhib-
itors significantly decreased control PGE excretion rates, and
prevented an increase in PGE excretion by hrIL-l (Fig. 4). The
24 average control PGE excretion rate of rats receiving no pre-
treatment was 312 39 pg/mm (N 14). Treatment with
ibuprofen or indomethacin decreased this rate to 143 24
pg/mm (N 7), and 123 23 pg/mm (N = 5), or by 54% (P <
0.01) and 61% (P < 0.02), respectively.
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Fig. 6. Effect of cyclooxygenase inhibition on the nairiuretic response
to 3 tg hrIL-1. The natriuresis was attenuated in rats pretreated with
ibuprofen and eliminated with indomethacin pretreatment. Sodium
excretion was calculated as the difference from the average control
values, which were: 0.8 0.2 ,aEqlmin (-c-, 3 g hr IL-I), 1.6 0.3
Eq/min (-•-, + ibuprofen) and 0.6 0.1 pEq/min (-•-, +
indomethacin).
natriuresis. It seems unlikely that this slight increase in pressure
is sufficient to account for a fourfold increase in sodium
excretion [26, 27]. Second, the natriuresis does not appear to be
dependent upon an increased filtered load of sodium, since
glomerular filtration rate was not significantly changed by IL-i
administration. Thus, systemic injection of IL-i apparently
inhibits net tubular sodium reabsorption. Since potassium ex-
cretion was unchanged while urine flow was increased, a
diuretic effect in the distal portion of the nephron is suggested.
Third, the natriuresis does not appear to be secondary to
general renal vasodilation since effective renal plasma flow was
unchanged following IL-i administration. However, effective
renal plasma flow, as assessed by PAH clearance, is thought to
represent primarily cortical plasma flow [28]. Thus we cannot
rule out a specific increase in medullary blood flow as contrib-
uting to the natriuretic mechanism. Finally, the natriuresis does
not appear to be related to the increase in body temperature,
since rats injected with 24 g hrIL-l demonstrated a maximal
natriuretic response without a significant febrile response. This
conclusion is consistent with previous results from human
The effect of hrIL-l on urinary PGE excretion is consistent
with the hypothesis that renal prostaglandins mediate the natri-
uresis. The excretion rate of PGE increased promptly (within 20
to 40 mm) following injection of IL-l. We measured PGE2 since
it is the most predominant renal prostaglandin, and is natriuretic
when infused intravenously [29]. Excretion rate was used as an
index of synthesis which occurs primarily in the medulla [30].
Although most renal PGE is rapidly metabolized within the
kidney, a fraction is excreted in the urine. Stop-flow studies
indicate that PGE enters tubular fluid in the loop of Henle [31].
Circulating PGE, on the other hand, does not appear intact in
the urine [321 due to rapid pulmonary metabolism [33]. Thus,
urinary PGE is thought to represent predominantly renal syn-
thesis [34]. Accordingly, increased PGE excretion indicates
that IL-I stimulates renal PGE release into the urine, and is
consistent with the hypothesis that IL-i induces renal PGE
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Fig. 5. Temporal relationship of sodium
excretion (—) and PGE excretion ( ). The
—1 peak of POE excretion preceeded that of Na
excretion following injection of 24 g hr IL-I.120 Similar time courses occurred following
injection of 1.5 or 3 Lg hr IL-l.
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subjects: following treatment with endotoxin, natriuresis en-
I 1 1 sued even when fever was suppressed by pretreatment with
Controi 0 20 40 60 80 100 120 aspirin [7].
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synthesis. Stimulation of prostaglandin synthesis has been
demonstrated in several other tissues including brain, muscle,
endothelial cells, chrondocytes, fibroblasts and macrophages
[35].
One might argue that increased PGE excretion may not
represent increased renal synthesis, but rather may be an
indirect effect of IL-i. For example, changes in urine flow rate
may affect PGE excretion rate independent of changes in
synthetic rate, Several studies have indicated that PGE excre-
tion rate increases when urine flow increases [36, 37]. The
increased excretion rate is not thought to represent increased
renal synthesis, but rather accelerated entry into the urine, as
would occur if PGE release into urine were diffusion limited.
Accordingly, the significance of increased PGE in the presence
of diuresis produced by other experimental manipulations has
been difficult to interpret. However, in our studies increased
PGE excretion preceeded diuresis (Fig. 5), and thus was not
secondary to increased urine flow. This temporal relationship is
consistent with a causal role of increased PGE in the natriuretic
response; bolus injection of hrIL-l induces prostaglandin syn-
thesis which in turn increases Na excretion. The delay of
natriuresis following hrIL-l injection may relate to the lag time
of this intermediary step.
The dose-response relationship of both POE stimulation (Fig.
4) and natriuresis (Fig. 3) is consistent with a causal role of PGE
in natriuresis. Increasing the dose of hrIL-l resulted in greater
stimulation of urinary PGE and greater natriuresis. The large
stimulation which occurred with the largest dose of IL-l indi-
cates that IL-l can be a potent stimulator of renal PGE.
The results of the indomethacin and ibuprofen experiments
provide further support for a causal role of PGE in natriuresis.
Both cyclooxygenase inhibitors significantly reduced control
PGE excretion, prevented the stimulation of PGE by interleu-
kin-i, and either attenuated or prevented natriuresis. However,
natriuresis occurred in a few of the animals treated with
ibuprofen. Renal cyclooxygenase inhibition may have been
incomplete in rats pretreated with ibuprofen. None of the rats
which received pretreatment with indomethacin exhibited natri-
uresis. Although urinary PGE was not increased by IL-I in the
ibuprofen treated rats which responded with natriuresis, a
moderate increase in intrarenal PGE may have occurred which
was not sufficient to cause a detectable increase in urinary POE.
Alternatively, it is possible that PGE is not the sole mechanism
of IL-i-induced natriuresis.
Our findings of a natriuretic effect of IL-l are in agreement
with those of a recent study [38]. The authors found a natri-
uretic effect of a similar dose of hrIL-l (2.5 sg). They also
concluded that the natriuresis was independent of increased
glomerular filtration rate, but based their conclusion on a
comparison between single clearance measurements made one
to two hours following injection of either IL-I or the IL-l
vehicle, by collection of voided urine. The effects of IL-i on
blood pressure and renal plasma flow were not studied. Flow-
ever, in contrast to our findings, the natriuresis to IL-I was not
inhibited by treatment with indomethacin. The only difference
between those studies and the present report was the time of
indomethacin treatment. They administered a similar dose of
indomethacin just prior to the IL-l injection, whereas in our
studies cyclooxygenase inhibitors were given two to four hours
prior to the injection and followed by a constant infusion. Since
urinary prostaglandins were not measured, it is unclear whether
indomethacin inhibited renal prostaglandin production in re-
sponse to IL-I in their studies.
Although a role of urinary prostaglandins in natriuresis has
been extensively studied, the conditions under which prosta-
glandins contribute to Na homeostasis has remained controver-
sial. Intravenous administration of PGE produces natriuresis
[291, but it has been argued that this may represent a pharma-
cological effect. The effect of cyclooxygenase inhibition on
sodium excretion is less clear-cut, In human and animal studies,
some investigators have found either decreased salt excretion
or no effect, while a few others have found increased salt
excretion [13]. The variable results may be due to the state of
salt or water balance, and presence or absence of anesthesia
[13]. Decreased salt excretion following administration of cy-
clooxygenase inhibitors has been more consistently observed in
anesthetized animals, than in conscious man or animals [13]. It
has been proposed that this may be due to the fact that plasma
renin is increased in anesthetized animals [39], since angioten-
sin stimulates prostaglandin synthesis. However, it is also
possible that these differences are due to the presence of
infection in animals used for acute experiments. Dogs obtained
for acute experiments often have chronic infections. Infection
may also be induced acutely by preparation of animals without
using sterile techniques. Our studies indicate that IL-I may be
an important factor which determines the role of endogenous
prostaglandins in Na excretion.
The observed influence of IL-i on renal sodium excretion
supports the view that virtually every organ system is affected
by IL-l, and, that natriuresis is part of the acute phase
response. Many components of the acute phase response are
beneficial adaptations which enhance survival of the host or
reduce the viability of certain pathogens. In the present studies,
rats injected with 3 jsg hrIL-i excreted an additional 425 Eq of
sodium during the two hour period of natriuresis, representing
a 5% decrement in total extracellular sodium. The intriguing
question of whether IL-i-induced reduction of extracellular
sodium and fluid volume enhances host resistance to infection
remains to be answered.
Natriuresis may occur when IL-i is released by monocytes
during a pyrogen response. Recent evidence that renal mesan-
gial cells produce IL-I [25], and the ascending limb of Henle
produces an inhibitor of IL-I [401 also raises the possibility that
IL-i could act as a local paracrine factor involved in intrinsic
regulation of renal function, Further study of IL-I-induced
natriuresis should help clarify the role of IL-l in renal function
as well as provide fundamental insight regarding the control of
sodium excretion.
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